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You cannot hope to build a better world without improving the individuals. To 
that end each of us must work for its own improvement and at the same time-
share a general responsibility for all humanity, our particular duty being to aid 
those to whom we think we can be most useful. 
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A obesidade tem sido descrita como uma causa de morbidade e 
mortalidade e estima-se que o número de mortes provocadas por cancro 
duplique até 2030, como resultado da epidemia de obesidade. A associação 
entre obesidade e vários tipos de cancro tem sido consistentemente 
estabelecida. No Linfoma de Hodgkin (LH), apesar de uma associação 
aparentemente variável para excesso de peso e obesidade (de acordo com a 
classificação da Organização Mundial de Saúde (OMS), baseado no índice de 
massa corporal), uma meta-análise contemporânea em estudos prospectivos 
estabeleceu uma associação significativa entre o índice de massa corporal 
(IMC) e risco para LH. Concordantemente, um recente estudo prospectivo em 
mais de 1 milhão de indivíduos demonstraram maior risco para LH em cada 10 
kg.m-2 unidades de aumento do IMC. Mesmo que a obesidade parece estar 
epidemiologicamente associada ao LH, a lógica biológica e mecanismos por de 
trás dessa relação causal permanecem em grande parte inexplicável. 
Cerca de 20% dos pacientes com LH morrem após recidiva ou 
progressão da doença. O LH é uma neoplasia linfóide derivada das células B, 
caracterizada pela presença de células malignas Hodgkin / Reed-Sternberg 
(HRS), em gânglios linfáticos, que ocasionalmente metastizam para a medula 
óssea. O LH apresenta a peculiaridade de que é o único entre vários tipos de 
cancro em que as células malignas são muito ultrapassados por células 
reativas e do estroma, e portanto, compostas por um microambiente tumoral 
altamente modulado pela interação intercelular. 
O excesso de adiposidade correlaciona-se com o aumento da produção 
de pró-adipoquinas tumorais e pró-angiogénicos e é caracterizado por um 
estado inflamatório crónico moderado. A nossa hipótese é que uma vez que a 
inflamação é um pilar na fisiopatologia do LH, o papel do tecido adiposo, seja 
através do sistema endócrino ou mecanismos parácrinos e tanto no seu local 
primário como na medula óssea, deve ser considerado. Para este efeito, foram 
medidas adipoquinas na medula óssea em casos com LH e controlos de forma 
a tentar revelar o efeito resultante da interação do microambiente da medula, 
que inclui as células HRS. 
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Durante 12 meses, 16 novos casos de LH elegíveis para biopsia de 
medula óssea e 11 controlos normais compatíveis para a idade, género e IMC, 
foram incluídos neste estudo. Concomitantemente, também foram obtidas 
amostras de sangue periférico. Uma membrana de matriz de adipocinas 
(Raybiotech) foi utilizada para determinar simultaneamente 62 moléculas 
desreguladas no líquido intersticial medular (LIM) em indivíduos com LH e com 
excesso de peso / obesidade (EP / OB). Em seguida, as conclusões do LIM 
foram validadas utilizando ELISA (Raybiotech), e correlacionado com os níveis 
circulantes de adipocinas.  
A osteoprotegerina esteve significativamente sobre-expressa no LIM de 
indivíduos com EP / OB comparativamente a indivíduos com IMC normal. No 
LIM de LH, diversas adipoquinas estiveram significativamente sub-expressas, 
nomeadamente, as proteínas do eixo do factor de crescimento da insulina 
(IGF), fatores de crescimento, proteínas envolvidas em redes reguladoras de 
imuno-inflamação e vias de remodelação óssea. De realçar, as proteínas de 
ligação ao IGF, a IGFBP-3 (6.4- vezes) e IGFBP-1 (13.2- vezes), que estiveram 
sub-expressas em pacientes com LH independentemente do estado de 
obesidade. A expressão de adipoquinas inflamatórias, interleucina (IL) -8, IL-1 
alfa (a), IL-12 e IL-1 beta (b), esteve diminuída (4.5- a 7.8- vezes) no LIM de 
LH, tal como, fatores de crescimento e hormonas, factor de crescimento 
transformante beta (TGF-β1) (5.2 vezes), o factor de crescimento de 
fibroblastos (FGF)-6 (7.6 vezes) e a leptina (12.6 vezes). A comparação de 
subgrupos extremos, LH simultaneamente EP / OB (n = 4) versus controlos 
com IMC normal (n = 4), corroborou o envolvimento potencial do eixo IGF na 
associação obesidade-LH. IGFBP-1, IGFBP-3 e de IGFBP-2 estiveram 
significativamente reduzidos (3.2- a 14.6- vezes) no LIM de pacientes com LH 
que tinham EP / OB. As adipoquinas inflamatórias IL-8, IL-1b e IL-12, estiveram 
correspondentemente reduzidas (3.9- a 8,0 vezes) nesse grupo. 
Embora o IMC esteja bem correlacionado com perímetro abdominal, 
somente o perímetro abdominal esteve inversamente associado com IGFBP-3 
e com os níveis de IGFBP-1 no LIM (r = -0.416, P = 0.039 e r = -0.473, P = 
0.017, respectivamente). 
Relativamente, aos parâmetros clínicos, uma forte tendência foi 
encontrada para baixos valores de IL-8 no LIM de pacientes com LH  e 
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sintomas B (com sintomas, média 0.02±0.004 pg/mL/µg, e sem sintomas, 
media 0.05±0.01 pg/mL/µg, P=0.052) 
Uma boa correlação foi encontrada para os níveis de adipoquinas entre 
LIM e soro. 
Este estudo abordou a associação causal da obesidade e do LH a partir 
da perspectiva do microambiente da medula óssea. A sua natureza 
exploratória em uma amostra biológica rara solicitou a utilização de uma matriz 
para identificar a desregulação de proteínas no LIM. 
Os resultados deste estudo piloto sugerem que as vias de adipocinas 
podem estar envolvidas na fisiopatologia do LH (nomeadamente o eixo IGF, 
alguns fatores de crescimento e hormonas, e marcadores inflamatórios), 
melhorando ainda mais a nossa compreensão da associação biológica da 
obesidade e o LH. O potencial efeito protetor da obesidade sobre 
microambiente da medula óssea do Linfoma de Hodgkin aplica-se 
exclusivamente ao prognóstico, tornando a associação obesidade-Linfoma de 
Hodgkin outro caso paradoxal da influência protetora da obesidade no cancro. 
Por outro lado, no presente estudo e tal como a maioria dos estudos 
dependem de medidas de IMC e classificação de obesidade segundo a OMS, 
no entanto, são estimativas imperfeitas de adiposidade e risco de doença, 
respectivamente. Estes métodos usados para estratificar o estado de 
obesidade do indivíduo não abrangem determinados depósitos de gordura 
localizados (por exemplo, tecido adiposo visceral), tendo estes, perfis de 
expressão de adipocinas específicos, contribuindo para tumores mais 
agressivos. Estudos epidemiológicos futuros devem abordar a composição 
corporal através de métodos mais precisos (por exemplo determinações de 
gordura visceral e subcutânea por tomografia computadorizada, gordura de 
todo o corpo por bioimpedância tetrapolar ou medições de gordura corporal 
locais mais específicos por meio de ressonância magnética, entre outros) para 
avaliar o distribuição de gordura num todo e a local em associação com LH.  
Em geral, os resultados deste estudo estão de acordo com um número 
muito limitado de relatórios sobre a obesidade como um fator de bom 
prognóstico para LH, embora em contraste com a evidência estabelecida de 
obesidade como fator de risco para o desenvolvimento de LH. Tomados em 
conjunto, um baixo perfil pró-inflamatório, juntamente com fatores de 
RESUMO 
XII 
crescimento diminuídos e leptina, e com o eixo IGF sobre-activado, 
encontramos na medula óssea de pacientes obesos HL são as principais 
características de um ambiente desfavorável para o início da metastização. Na 
obesidade, esperamos revelar que essas adipocinas são produzidos pelos 
adipócitos na medula óssea e para demonstrar que pode interferir com 
microambiente metastático no LH.  
Desta forma, os resultados aqui apresentados são esperados para 
promover novos esforços de pesquisa. 
 










Inflammation is a cornerstone in Hodgkin’s Lymphoma (HL) 
pathophysiology, so, the role of adipose tissue, either through endocrine or 
paracrine mechanisms and both at its primary site and in bone marrow, must be 
of importance. 
During 12 months, 16 new cases of HL eligible for bone marrow biopsy 
and 11 age-, gender- and body mass index (BMI)-matched normal controls 
were included in this study; matched samples of peripheral blood were also 
obtained. An adipokine antibody array was used to determine deregulated 
molecules in interstitial marrow fluid (IMF) of HLs and overweigth/obese 
(OW/OB) subjects. Findings in IMF were validated using ELISA, and correlated 
with circulating adipokine levels. Osteoprotegerin was significantly 
overexpressed in the IMF of OW/OB subjects compared with normal BMI. 
IGFBP-3 (6.4-fold) and IGFBP-1 (13.2-fold) were underexpressed in HL patients 
independent of obesity status. The expression of interleukin (IL)-8, IL-1 alpha 
(a), IL-12, and IL-1 beta (b), was depressed (4.5- to 7.8-fold) in the IMF of HLs; 
and the transforming growth factor (TGF)-β1 (5.2-fold), fibroblast growth factor 
(FGF)-6 (7.6-fold) and leptin (12.6-fold). The comparison of utmost subgroups, 
HLs simultaneously OW/OB (n=4) versus controls with normal BMI (n=4), 
corroborated the potential involvement of IGF axis in the association obesity-
HL. IGFBP-1, IGFBP-3 and IGFBP-2 were significantly reduced (3.2- to 14.6-
fold) in the IMF of HL patients who were OW/OB. The inflammatory adipokines 
IL-8, IL-1b and IL-12, were correspondingly reduced (3.9- to 8.0-fold) in this 
group. The abdominal perimeter was only inversely associated with IGFBP-3 
and with IGFBP-1 levels in IMF (r=-0.416, P=0.039 and r=-0.473, P=0.017, 
respectively). A strong trend was found towards lower IL-8 levels in the IMF of 
HL patients with B symptoms. A good correlation was found for adipokine levels 
between IMF and serum. 
Findings from this pilot study suggest that adipokine pathways might be 
involved in HL pathophysiology. 
 
















1. LITERATURE REVIEW 
1.1. Introduction overview 
 
Obesity has been described as a cause of morbidity and mortality and it 
is estimated that the number of deaths caused by cancer will double by 2030, 
as a result of the obesity epidemic [1]. The association between obesity and 
many cancer types has been consistently established [2]. In Hodgkin’s 
Lymphoma (HL), despite an apparently variable association with overweight 
and obesity (according to the body mass index-based World Health 
Organization classification) [3-7], a contemporary meta-analysis on prospective 
studies established a significant association between body mass index (BMI) 
and risk for HL [8]. Concordantly, a recent prospective study in over 1 million 
individuals demonstrated increased risk for HL each 10 Kg.m-2 units of increase 
in BMI [9]. Even though obesity seems to be epidemiologically associated with 
HL, the biological rationale and mechanisms behind this causal relationship 
remain largely unexplained.  
HL is characterized by an inflammatory microenvironment at the tumor 
site in lymph nodes [10, 11]. The distinctive HL’s malignant Hodgkin & Reed-
Sternberg (HRS) cells reciprocally interact with the inflammatory milieu resulting 
in tumors with survival and evasion advantages [10]. Besides age, inflammation 
and Epstein-Barr virus (EBV), little is known concerning predictive factors of HL 
aggressiveness [12, 13]. Noteworthy, despite the high cure rate, in advanced 
stage disease approximately 25% to 30% of patients are not cured with 
standard therapeutic regimens alone, and about 20% of patients still die after 
relapse or disease progression [12, 14]. In advanced stages, where bone 
marrow infiltration is common, the international prognostic score and other risk 
stratification instruments remain only modestly effective to predict disease 
progression and therapeutic response [15].  
Excess adiposity is regarded as a chronic inflammatory state, hence it is 
postulated that excess adiposity-mediated inflammation may play a role in 
promoting HL growth, survival and tumor immune evasion. We hypothesize that 
this accumulation of immune cells in HL, including T and B cells, neutrophils, 
eosinophils, and mast cells might be disturbed by excess adiposity, which is 
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known to modulate the immune system function [16, 17]. In addition to 
immunoinflammatory derangements, there is a systemic metabolic dysfunction 
in obesity that prompts altered circulating levels of pro-tumoral adipokines. 
Indeed, some of these adipokines have been associated with HL and advanced 
stages of disease [18-20]. Albeit the mechanisms of the causally invoked 
association between obesity and HL remain undetermined, a reasonable 
biological rationale supports plausibility for the relation of adipose tissue-
inflammation-HRS axis with HL aggressiveness. Taken together these obesity-
linked endocrine and paracrine mechanisms may contribute towards a 
favorable microenvironment for growth and spread of HRS malignant cells. 
Moreover, albeit still experimentally unproven, it is expected that the known 
paracrine action of adipocytes in the bone marrow microenvironment [21, 22] 
might facilitate HRS cells to metastasize and grow in the bone marrow. 
Taken together, these considerations suggest that research should 
establish definite biological mechanisms involved in the association between 
excess adiposity and HL, which will foster the development of new molecular 
markers based on adipokine’s pathways as indicators of clinical outcome and 
incorporated into prediction models. If confirmed, the effects of bone marrow 
adipocytes in metastatic HL cells might represent new potential therapeutic 
targets in this advanced stage of disease. 
 
1.2.  Mechanisms promoting Hodgkin Lymphoma’s 
 
HRS cells, despite their small representativeness in HLs (about 1%), are 
modulated by a mixed inflammatory microenvironment that influences tumor 
development [10, 23]. These unique features of HL are far outweighed by 
reactive and stromal cells [10]. Inflammation, among others, has been recently 
considered as a cancer hallmark [24]. In fact, survival, proliferation and 
immunoinflammatory mechanisms seem to have an important role in HL 
pathophysiology [10].  
The HL tumor microenvironment, in particular, the cytokine/chemokine 
pattern secreted by HRS cells and non-neoplastic circulating cells may 
influence the proliferation and survival of malignant cells [25, 26]. Among 
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others, HRS cells secrete several interleukins (ILs) (e.g., IL-1α, IL-4, IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-13), chemokines (thymus- and activation-regulated 
chemokine CCL17, TARC, and CCL22, MDC), macrophage colony stimulating 
factor (M-CSF), tumor necrosis factor- α (TNF-α) and β (TNF-β), transforming 
growth factor beta (TGF-β), soluble CD30 and chitinase-3-like protein 1 (YKL-
40), with autocrine tumor growth effect [25]. Among these, thymus and 
activation-regulated chemokine (TARC) and macrophage-derived chemokine 
(MDC), produced by HRS cells, are partially responsible for whittling HL 
microenvironment by inducing Th2 and Treg cells [25], which have been 
associated with reduced tumor immunosurveillance [27]. Moreover, paracrine 
actions were uncovered through upregulated pathways mediated by cytokine 
receptors (IL-2R, IL-6R, IL-9R, IL3R), macrophage colony-stimulating factor 
receptor (M-CSFR), tumor necrosis factor receptors (TNFR1, TNFR2), CD30 
and CD40 [28]. Downstream signaling through the IL-3/IL3R pathway induces 
growth and extends survival in HL cells [29]. Paracrine signals may arise from 
non-malignant tumor-infiltrating cells in HL microenvironment (e.g., eosinophils, 
mast cells, neutrophils and macrophages) [10]. The nuclear factor-kappa B (NF-
kB) and Janus Kinase-signal transducer and activator of transcription (JAK-
STAT) pathways have been identified as important modulators in HL [26]. 
Activation of the NF-kB pathway, which is involved in the expression of multiple 
anti-apoptotic factors and pro-inflammatory cytokines, reduces the expression 
of CD99, a marker associated with HRS cells phenotype  
Some authors identified circulating proteins as candidate biomarkers for 
HL, which demonstrated prognostic value and accuracy to predict the response 
to therapy. These molecules act at HL site and modulate the outcome [30-32]. 
A recent report showed increased levels of serum interleukin 6 (IL-6) and YKL-
40 at diagnosis, which were correlated with stage of disease [18].  
1.3.  Obesity and Hodgkin Lymphoma 
 
Obesity is currently considered epidemic worldwide [33]. Overweight and 
obesity are defined as excessive accumulation of adipose tissue and are 
associated with increased risk of morbidity and premature mortality. Besides 
other downstream health consequences, epidemiological studies reported 
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obesity as a risk factor for cancer [2, 34, 35]. In the United States of America 
the estimated risk of death from cancer in morbidly obese (BMI ≥ 40 kg/m2) was 
1.5 in men and 1.6 in women [34], whereas in Europe, obese have 1.5 to 3.5 
higher risk of having cancer [1]. Alongside, it has been estimated that 
approximately 30% of cancer deaths might be related with dietary and 
behavioural factors, namely, high BMI, low intake of fruits and vegetables, lack 
of exercise, smoking and alcohol abuse. A recent meta-analysis based on 
prospective studies reported that obesity (BMI ≥ 30 kg/m2) was positively 
correlated with risk of HL [8]. Indeed, a number of studies reported a positive 
relation of obesity with hematologic malignancies, including Hodgkin’s 
lymphoma [3-7, 9, 35], even though others have not found such an association 
[36-42] (Table 1). Noteworthy, 2 studies found a protective role for obesity in the 
development of HL. Despite the batch of positive association studies between 
obesity and HL, it is important to highlight the time when the anthropometric 
assessments were made and the outcomes considered. Indeed, some authors 
consider that this potential protective effect of lower BMI in cancer may be due 
to the effects of cancer-related cachexia, a more deleterious than the potential 
adverse events related to a higher BMI [43]. 
Obesity may increase the risk for developing HL, even though its effects 































































Most studies rely on body mass index measures and World Health 
Organization classification of obesity, although BMI and WHO cutoffs are 
imperfect estimates of adiposity and disease risk, respectively [44-46]. 
Additionally, these methods used to stratify subject’s obesity status do not 
account for local fat depots (e.g., visceral adipose tissue), which were shown to 
have adverse specific adipokine expression profiles, contributing towards more 
aggressive tumors [47-49]. Future epidemiological studies should address 
these issues by using more precise methods (e.g. visceral and subcutaneous 
fat determinations by computed tomography scan, whole body fatness by 
tetrapolar bioimpedance, or local and whole body fat measurements through 
magnetic resonance imaging, among others) to evaluate whole and local body 
fatness in association with HL.  
At present, the adipocyte is no longer considered a passive component 
of human metabolism. It is known as an endocrine/paracrine organ that exerts 
many biological effects through production of growth factors, cytokines and 
hormones [50]. These biologically active molecules secreted primarily, partially 
or exclusively by adipocytes, known as adipokines, have a significant role in 
regulating angiogenesis and tumor growth [51]. In fact, the importance of the 
interaction between cancer cells and surrounding stroma cells has been 
increasingly accepted. These interactions are particularly prominent in 
environments rich in adipocytes [52]. The excess body fatness is characterized 
by a chronic low-grade inflammatory state with altered circulating levels of 
adipokines, including IL-6, IL-8, leptin, adiponectin, TNF-α, vascular endothelial 
growth factor (VEGF), osteopontin (OPN), haptoglobin (Hp), YKL-40, among 
others [53-55] (Figure 1). These molecules impact cancer-related mechanisms 
such as cell proliferation, apoptosis and migration [56, 57]. The altered 
secretion of adipokines in obesity deranges metabolic homeostasis, together 
with influences in immunological status [58] (Figure 1). In this context, the 
evaluation of markers related to obesity and immune response in HL, might 
reveal new opportunities for understanding the mechanisms responsible by the 
association between obesity and HL. Various adipokines have already been 
shown to be linked with HL risk and with advanced stage of disease, namely IL-
6 and interleukin 7 (IL-7) [18, 19, 59], while others endure as promising targets 
for future studies (e.g., leptin, adiponectin, resistin, HGF, visfatin, …). Thus, the 
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chronic inflammation sustained by expanding adipose tissue may modulate host 
immunosurveillance [16] and exert a direct effect at both local tumor 
microenvironment and distant tumor cells through the systemic effects of 
endocrine signals (Figure 1). 
Angiogenesis is a well-established hallmark of tumor development both 
in solid tumors and hematological malignancies (including HL). Reasonable 
data, mostly supported by retrospective immunohistochemistry evaluations, 
stands for a relevant role of angiogenesis in HL, where a shift towards an 
angiogenic phenotype is observed as result of unbalanced angiogenic versus 
anti-angiogenic stimulus [60]. Interestingly, many of the adipokines 
overexpressed by adipose tissue in obesity are well-known for their potent pro-
angiogenic effects [53]; therefore, it seems plausible that these adipokines 
might mediate the causally invoked association between excess adiposity and 
HL through a modulatory effect in angiogenesis (Figure 1). 
Besides adipokine secretion, the expanding adipose tissue is also 
infiltrated by macrophages with M2-to-M1 differentiation, further contributing 
towards the obesity-associated systemic chronic inflammation and insulin 
resistance [58, 61] (Figure 1). Leptin and adiponectin, hormones exclusively 
produced by adipocytes and with opposing effects in obesity and cancer, 
contribute to the polarization of macrophages [62, 63], respectively. 
Interestingly, in HLs the presence of CD68+ tumor-associated macrophages is 
indicative of poor prognosis [23, 64], whereas paediatric HL patients have 
higher adiponectin levels [65]. Recently, the soluble circulating CD163 and 
TARC were identified as possible biomarkers of HL [30]. CD163 is a known 
marker for M2 macrophages polarization and a receptor for Hp, which is a major 
acute phase protein overexpressed in conditions such as obesity and HL [66, 
67]. Nonetheless, Hp is induced not only by IL-6 downstream transcription 
factor STAT3, but also by hypoxia-inducible factor-1α (HIF-1α) that are 
overexpressed in HL [68]. Therefore, excess adiposity may interfere with 
malignant cell signaling pathways and to modulate macrophage differentiation, 
both of which can impact the tumor. This obesity-driven inflammatory 
environment exerts tumor-promoting effects, due to alter inflammation pathways 
implicated in cell proliferation, survival, angiogenesis, and metastasis 
associated with cancer (Figure 1). These potentially unrevealed links should 
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foster experimental research to uncover the impact of these obesity-associated 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4.  Bone marrow adipocytes and Hodgkin Lymphoma  
 
Adipocytes in the bone marrow have been implicated as regulators of 
marrow microenvironment [21, 69], and present a distinctive phenotype, which 
resembles both, white and brown adipose tissue [70]. Besides 
representativeness, bone marrow adipocytes present an unilocular lipid 
morphology similar to white adipose tissue, and are a unique adipose depot that 
overexpresses genes associated with cell differentiation and with inflammation 
[71, 72]. Amplified bone marrow adiposity due to diet-induced obesity in mice 
was recently implicated in altered bone metabolism and inflammation within the 
bone microenvironment [73]. Adiposity in bone marrow is modulated by high fat 
diet, diabetes, aging, dyslipidemia and obesity, through diverse pathways that 
comes together to regulate the expression and activity of a key pro-adipogenic 
transcription factor, the peroxisome proliferator-activated receptor γ2 (PPAR-γ2) 
[74].  
Bone marrow adipocytes behave as energy suppliers to bone 
physiological functions, including bone remodeling [69, 75]. In addition to 
energy storage, these adipocytes secrete adipokines and fatty acids that impact 
significantly on metabolism and function of other neighboring cells in the bone 
microenvironment [72, 76]. From this interaction in bone marrow milieu, an 
inverse relationship has been described between osteoblastogenesis and 
adipogenesis, with a negative correlation of marrow adiposity with osteoblast 
number and bone mineral density [74]. In fact, several factors produced in the 
bone marrow may exert a regulatory role in local adipocytes, as well as 
adipokines secreted in marrow adipocytes might influence other cellular players 
through a paracrine effect [76] (Figure 2).  
Hodgkin’s lymphoma involving the bone marrow ranges between 2 to 
32%, with an average incidence of 10% [77]. Although the chronic low-grade 
inflammation and the upregulated secretory profile associated with obesity may 
exert endocrine effects, we should not overlook paracrine actions of adipocytes 
in bone marrow microenvironment bearing metastasis from primary HL tumors 
[22]. The crosstalk between adipocytes and cancer cells has been 
demonstrated to support progression and aggressiveness of tumors in other 
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oncologic models [52, 78-80], as well as metastatic cell growth in the bone 
marrow [81]. Fat cells seem to be able of translocating stored lipids to 
metastatic tumor cells, ultimately driving cancer growth and motility [78, 82]. 
The complex interaction between components of bone marrow, including 
adipocytes and eventually tumor cells, is depicted in Figure 2. 
In other oncologic models, the fatty acid binding protein 4 (FABP4) was 
shown to be implicated in adipocyte-tumor cell interactions [78, 81]. 
Notwithstanding FABP4 is transcriptionally regulated by PPARγ, this lipid 
chaperone also controls PPARγ [83, 84], while both seem to be involved in 
adipocyte-induced metabolic switching in cancer microenvironment. 
Interestingly, in B lymphoma cells the decreased PPARγ expression was related 
with increased proliferation and survival, and initiation of inflammatory 
pathways, specifically the activation of nuclear factor kappa B (NF-κB) [85], 
further underlining the link between inflammation and neoplastic progression. 
Primary cancer-derived metastases that home to the bone are by 
themselves incapable of inducing bone resorption. However, these aggressive 
malignant cells interact with bone constituents and influence the function of 
bone-degrading cells (osteoclasts), inducing osteolytic lesions [86]. Bone 
metastases from HLs have been described as osteolytic [87, 88]. The complex 
interaction of tumor cells with bone marrow microenvironment, including 
adipocytes, exerts profound influence in proteolytic degradation and bone 
resorption, enabling metastasis allocation. Obesity and aging are known 
effectors of bone remodeling by forming adipocytes instead of osteoblasts, 
which will lead to increased osteoclast activity and osteoporosis [76, 89]. A key 
enzyme for osteoclastic bone resorption is cathepsin K (CTK) that degrades the 
bone matrix protein collagen I and other proteins of the bone matrix [90]. CTK 
expression within the bone marrow milieu is high in osteoclasts and adipocytes, 
and results in accelerated bone turnover [91] and in a potential contribution to 
the metastatic process. CTK production was also described in cancer cells that 
metastasize to bone [92]. CTK acts by upregulating the processing of its 
substracts extracellularly, including the secreted protein acidic and rich in 
cysteine (SPARC or osteonectin) that interacts with collagen I and other matrix 
proteins to attract and anchor malignant cells in the bone [91]. In addition, 
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VEGF, a growth factor known to be involved in tumor cell migration and in 
osteoclast differentiation and migration has been proposed to be modulated in 
the bone microenvironment by CTK cleavage [90, 93]. Besides the key role of 
CTK in degrading collagen I, it also seems to be relevant for adiponectin 
cleavage, which may be a mechanism to stimulate osteoclastogenesis via 
increased expression of receptor activator of NFκB ligand (RANKL), to 
modulate marrow fatness, or to influence adiponectin-mediated suppression of 
tumorigenesis [94, 95]. Bone marrow adipocytes also stimulate osteoclast 
differentiation and activity by directly secreting RANKL [96].  
Bone marrow adipocytes are a significant secondary source of leptin and 
IL-6, whereas only trace amounts of IL-1β and TNF-α were found [97]. These 
molecules exert interactive regulatory mechanisms between them, in order to 
modulate the marrow environment, controlling the proliferation and 
differentiation of hematopoietic precursors as well as the maturation of stromal 
cells [98]. Given the importance of JAK/STAT signaling in HL malignant cells 
and that leptin and IL-6 downstream signals are mediated by this pathway [99, 
100], we hypothesize these adipokines might influence HRS cell survival and 
proliferation both through an endocrine mechanism in lymph nodes and by a 
paracrine effect in the bone marrow. Since leptin and IL-6 are upregulated in 
the serum of obese subjects, they can partially explain the association between 
excess adiposity and HL. Only few unpowered studies have measured serum 
leptin and adiponectin levels in HL patients, mostly children, with inconclusive 
mixed results [65, 101, 102]. With respect to IL-6, several reports demonstrated 
that it was a relevant cytokine for HRS proliferation and survival and a useful 
biomarker of aggressiveness [103, 104]. It is largely unknown whether bone 
marrow adipocytes behave differently in presence of HL malignant cells. Thus, 
further investigation on the interactions of bone marrow adipocytes with HRS 
cells is required to clarify many unanswered questions and advance knowledge 
with potential clinical translation. 
Here, we hypothesize that when HRS cells are metastasized to bone 
marrow, resident adipocytes may have a role in bone remodeling, yielding 
tumor cells with adipokines and fatty acids to boost growth and survival, 
concurring towards worst prognosis. Further clinical studies should follow 
disease behavior in HL obese patients and evaluate the impact of intervening in 
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obesity on HL prognosis. Therefore, obesity and its effect on bone marrow 

































































































































































































































































































































































































































































































































































































































































































































































































































































2.  OBJECTIVES 
 
2.1. General objectives 
 
 The overall goal of this study is to examine the association between 
excess adiposity and Hodgkin’s Lymphoma and contribute towards untangling 
the mechanistic clues behind. Ultimately, we aim at characterizing 
mechanistically the obesity-HL relationship from a molecular, cellular and 
genetic perspective. 
 
2.2. Specific objectives 
 
 
- Evaluate whether and which adipokine levels in the bone marrow are altered 
according to obesity, pathological status and disease aggressiveness, using a 
multiplexed array.  
- Correlate the levels of altered adipokines on the bone marrow with peripheral 

















3. MATERIAL AND METHODS 
3.1. Population 
3.1.1. Patients and sample collection 
 Iliac crest or sternum bone marrow aspirates and matched peripheral 
blood samples were obtained at the same time of staging procedures from 16 
patients (median age, M=31 years; interquartile range, IQR=15 years) 
diagnosed and treated at the Department of Onco-hematology of the 
Portuguese Institute of Oncology Porto Centre (IPO Porto) and from 11 marrow 
donors (M age=28 years; IQR=12 years), recruited from the Laboratory of 
Cellular Therapy at IPO Porto, and the Immunotherapy Unit and Clinical 
Pathology Department of Sta Maria Hospital, Lisbon. All individuals complied to 
participate by signing a written informed consent, whereas the study was 
approved by the ethics’ committees of participating institutions. Research was 
conducted according to principles of the Declaration of Helsinki. 
Participants and donnors were enrolled between May 2014 and May 
2015. HL patients were included at the time of the first visit to confirm diagnosis 
in the Department of Onco-hematology of IPO Porto. One patient was excluded 
from final analyses since the final histological diagnosis was histiocytic 
sarcoma. Donors were selected to match HL’s by age, gender and BMI. Bone 
marrow and peripheral blood samples were collected in the morning, and for 
HLs at the time of diagnosis and before starting treatment.  
 Subsequent studies on the relevance of adipokine pathways in HL will be 
conducted in primary disease location at malignant lymph nodes. Paraffin-
embedded tumor samples from a retrospectively recruited cohort of HL patients 
(n=71) at the Pathology Department of Sta Maria Hospital will be used for 
studying the expression of altered adipokines and its receptors. This ensuing 
study includes 71 HL patients diagnosed between 2009 and 2013 and with 
clinical follow-up documented at the same hospital. Interestingly, at least 30 
patients have matched paraffin-embedded samples of bone marrow infiltration 
and 11 mediastinal malignant tissue. 
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3.1.2. Anthropometric measurements 
Anthropometric data included height, weight and abdominal perimeter, 
and followed standardized procedures: a digital scale and a wall-mounted 
stadiometer were used for weight and height determination; abdominal 
perimeter was measured, with precision up to 0.1 cm, at the midpoint between 
the lower rib margin and the iliac crest. Body mass index (BMI) was calculated 
using the algorithm [weight (kg)/height2 (m)], and thereafter categorized 
according to WHO classification into underweight (BMI < 18.5 kg/m2), normal 
BMI (BMI = 18.5 to 25 kg/m2), overweight (BMI = 25 to 30 kg/m2) and obese 
(BMI ≥ 30kg/m2). In this study, we separated patients into only two groups: 
normal BMI (BMI < 25 kg/m2) and overweight/obese (OW/OB) (BMI ≥ 25kg/m2). 
 
3.2. Isolation of biological specimens from the bone marrow and 
blood 
3.2.1. Bone marrow and blood samples processing 
 The first sample during the bone marrow (BM) biopsy was collected to a 
heparinized tube with 200 uL citrate, and immediately inverted with care, to 
avoid hemolysis and clot formation. The BM was centrifuged in Ficoll gradient 
(Histopaque, Sigma) and centrifuged at 1500 rpm at room temperature for 
30min. The upper layer with adipocytes was washed and the isolated 
adipocytes were processed to RNA and stored at -80ºC. The interstitial marrow 
fluid (IMF) was collected, centrifuged and stored at -80ºC. 
  Stromal cells were also collected from the gradient centrifugation, 
washed and ressuspended in erythrocyte lysis buffer (NH4Cl). Isolated stromal 
cells were partially fixed in slides with acetone and stored at -20ºC, while the 
remaining pellet was processed to RNA and stored at -80ºC. 
  Peripheral blood was collected into one EDTA tube and one-
biochemistry tube, and plasma and serum removed, respectively. For 
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3.3. Adipokine’s protein array on interstitial marrow fluid 
3.3.1. Adipokine profiling - Multiplex measurements 
 
 The IMFs were used to run a multiplex array (AAH-ADI-1-8 Obesity 
Adipokine antibody array C series 1, RayBio®) for simultaneous determination 
of 62 adipokines in matched HL patients group and a control group, by BMI, 
age and gender. The previously calculated sample size was 8 individuals in 
each group (with a α=0.05, β=0.8, rate=1.0 and assuming a difference of 25 
intensity units between groups).  
Briefly, membranes were initially incubated with blocking buffer under 
gentle shaking for 30 minutes, followed by overnight incubation with IMF at 4ºC. 
The membranes were then washed several times and incubated with a 
biotinylated antibody cocktail for 2 hours at RT. After another washing step, the 
membranes were labeled with HRP-Streptavidin for 2 hours. Signal intensity 
was detected by chemoluminescence after adding the substrate and revealed 
on X-ray film, using several exposure times. 
3.3.2. Microarray data extraction and analysis 
 
 Signal intensities (intensity by milimeter squared) were calculated using 
2-D densitometry software. Selection of films with appropriate exposure time 
followed the criteria of strong spot signals vs. low background response, strong 
positive control spot signals and similarity between positive control signals. We 
used the software ImageJ with protein array macros for quantification of signal 
intensity, while ensuring the same extraction circle dimensions (area, size, and 
shape).  
Following raw numerical densitometric data extraction, the background 
was subtracted and the data normalized to the positive control signals, within 
each membrane. In agreement with manufacturer’s intructions an algorithm was 
used to calculate the fold expression between analytes [X(Ny) = X(y) * P1/P(y)]. 
MCP-3 and TNF-α were excluded from the protein array data, once 
missing or negative values existed for more than 8 of the 16 samples. Then, 
adequate adjustments of measurements from array data were log2-transformed 
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to become normally distributed. There were imputed the missing values using R 
package. Statistical analyses were performed using LIMMAR R package, and 
the adjusted P-value was considered statistically significant when <0.1.	
3.4. Validation of adipokine concentration in IMF by ELISA 
 Four of the most differentially expressed adipokines in IMF (IGFBP-1, 
IGFBP-3, IL-8 and OPG), were quantified in IMF and matched serum using pre-
coated human ELISA kits (RayBiotech®). Briefly, samples were incubated for 
2.5 and then washed. After incubation with biotinylated antibody for 1 hour and 
wash steps, streptavidin was added and incubated for 45 minutes. When the 
substrate was added and the color developed in proportion the reaction was 
stopped and optical densities determined in a microplate reader set to 450 nm.  
Log transformation of data was computed to allow curve fitting (nonlinear 
regression), interpolation of values, followed by conversion to concentration. 
GraphPad Prism 5 software was used to create the standard curve and 
interpolate adipokine concentrations. Total protein concentration in IMF and 
serum was measured using the Bradford method. 
The intra- and inter- assay precisions were <10% and <12% for each 
assay, and the minimum detectable amounts were 5 pg/mL for IGFBP-1, 80 
pg/mL for IGFBP-3, and 1 pg/mL for both IL-8 and OPG. 
3.5. Statistical analysis 
Departure from normality of continuous variables was tested using 
Shapiro-Wilk test. Then, parametric or non-parametric tests were accordingly 
used to compare means between groups. Independent samples t-test and 
Mann Whitney were used as appropriate, whenever variables were non-
parametric. Determination of the Spearman correlation coefficient was applied 
to test the strength of association between continuous variables. Analyzes were 















4.1.  Characterization of participants 
	
During 15 months, 16 new cases of Hodgkin Lymphoma were recruited to 
participate in this study, together with 11 age-, gender- and BMI-matched 
controls. Age, gender and anthropometric information from each group are 
depicted in Table 2. No differences were found between groups in any of those 
variables. Anthropometrically, in this study we achieved a reasonable matching 
between HL and controls, once waist and BMI values were similar, as well as 
for obesity classification. 
 
Table 2: Comparison of age, gender and anthropometric variables between Hodgkin’s 




(n=16) P-value ** 
Age (years) 29.6 ± 2.5 29.4 ± 1.9 0.951 
Height (cm) 167.9 ± 3.3 170.4 ± 1.7 0.517 
Weight (Kg) 72.0 ± 5.9 72.7 ± 3.2 0.906 
Waist (cm) 84.8 ± 4.2 89.0 ± 12.0 0.402 
BMI (Kg/m2) 25.3 ± 1.5 25.1 ± 1.1 0.906 
Gender    
Female 6 (54.5) 10 (62.5) 
0.710 * 
Male 5 (45.5) 6 (37.5) 
WHO classification 
Normal weight  
(18.5 - 25 kg/m2) 6 (54.5) 11 (68.8)  
0.453 * Overweight/obese  
(≥ 25 kg/m2) 5 (45.5) 5 (31.2) 
Data is presented as mean ± standard error of mean or as frequencies. * Chi-
square test; ** Independent measures t-test. HL, Hodgkin Lymphoma; BMI, 
Body mass index; WHO, World Health Organization. 
 
Starting from the whole recruited population from which we had collected 
bone marrow (n=16 HLs and n=11 donors), we undertook a selection of cases 
(by gender, ± 5 years of age, by obesity category) to more precisely match 
patients to allow the comparison adipokines in IMF through an adipokine protein 
array. Besides stratification by disease status (n=8 HLs and n=8 donnors), we 
were able to categorize further within each group for obesity status (for HLs, 4 
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obese/overweight and 4 normal weight patients, and for controls also 4 
obese/overweight and 4 normal BMI subjects) (table 3). 
 
Table 3: Confirmation of selection for stratified analysis by obesity status, for 
secondary analysis in protein array 
 Controls (n=8) HLs (n=8)  Overall (n=16) 
 Age BMI Age BMI  Age BMI 
Normal BMI 
(n=4) 24.4±3.3 21.8±1.9 22.5±6.1 22.1±1.6  23.5±4.7 22.0±1.6 
OW/OB 
(n=4) 33.5±10.2 27.5±3.1 33.5±6.2 29.9±4.7  33.5±7.8 28.7±3.9 
P-value * 0.142 0.021 0.045 0.020  0.008 0.001 
* Independent samples t-test comparing by BMI the normal BMI versus OW/OB groups. Normal 
BMI and OW/OB groups have n=8 subjects each on overall analysis. HLs, Hodgkin Lymphomas; 
BMI, body mass index; OW/OB, overweight/obese 
 
For stratified secondary analysis in protein arrays, we were able to 
separate samples within each group (control and HL) by BMI, and confirmed 
that the normal weight group have significantly lower BMI than 
overweight/obese group, independent of the pathology group. 
A descriptive clinicopathological characterization of participants with HL 
is depicted in Table 4 by obesity status. There are no clinical or pathological 
features associated with obesity, classified by WHO groups. Adding up to the 
HL’s descriptive, 15.4% HL patients were at risk level 3, and over 50% were 
treated with Adriamycin/Bleomycin/Vinblastine/Dacarbazine (ABVD), followed 















Table 4: Clinicopathological characteristics of Hodgkin’s Lymphoma patients by body 
mass index group 
a Ann Arbor staging. b Include fever, night sweats in the last month, and/or > 10% weight loss in the 
last 6 months. NW, normal weight; OW/OB, overweight/obese; ABVD, doxorubicin, bleomycin, 
vinblastine and dacarbazine; RT, radiotherapy. * Chi-square test, except for age, where 
independent measures t-test was used. 
 
4.2. Adipokines in interstitial marrow fluid of HLs and OW/OB 
 
The search for altered adipokine pathways in the bone marrow interstitial 
fluid was initially focused on the utilization of a protein array, in order to get 












Age (years) 26.7 ± 7.5 34.0 ± 4.9 29.4 ± 7.5 0.054 
Gender     
Women 6 (60.0) 4 (66.7) 10 (62.5)  
Male  4 (40.0) 2 (33.3) 6 (37.5) 0.790 
Clinical Stage a 
I 2 (20.0) 2 (33.3) 4 (26.7)  
II 5 (50.0) 3 (50.0) 8 (53.3)  
IV 3 (30.0) 1 (16.7) 4 (13.3) 0.766 
Histopathology      
Nodular sclerosis 8 (88.9) 4 (66.7) 12 (80.0)  
Lymphocyte predominance 1 (11.1) 2 (33.3) 3 (20.0) 0.292 
B-symptoms     
No 8 (80.0) 4 (66.7) 12 (75.0)  
Yes b 2 (20.0) 2 (33.3) 4 (25.0) 0.551 
Risk level     
0 4 (44.4) 1 (25.0) 5 (38.5) 
0.738 
1 3 (33.3) 2 (50.0) 5 (38.5) 
2 1 (11.1) 0 (0) 1 (7.7) 
3 1 (11.1) 1 (25.0) 2 (15.4) 
Treatment     
ABVD 3 (27.3) 0 (0) 3 (18.8) 





Figure 4: Representative blot membranes of adipokine expression in interstitial 
marrow fluid of one donor and one HL.  
Comparison of the amount of adipokines in interstitial marrow fluid of controls and 
Hodgkin’s Lymphoma using an adipokine membrane array. Representative 
membranes from one control and one HL (Two of sixteen arrays). IGFBP-3, insulin 
growth factor binding protein 3; IGFBP-1, insulin growth factor binding protein 1; FGF-
6, Fibroblast growth factor 6; OPG, osteoprotegerin; IL-8, interleukin 8; IL-1a, 
interleukin 1 alpha; HL, Hodgkin’s Lymphoma 
 
Adipokine protein array analyses demonstrated that from 62 proteins 
only OPG was overexpressed in the marrow fluid of overweight/obese subjects 
compared with normal BMI, overall and within HL group of patients (table 5). 
 
Table 5: Altered adipokines in interstitial marrow fluid of overweight/obese subjects. 
Protein name Description Fold change Unadjusted P 
Overweight/obese versus normal weight 
All subjects 
OPG Osteoprotegerin +2.5 0.009 
Controls 
none --- --- --- 
Hodgkin Lymphoma 
OPG Osteoprotegerin +4.0 0.004 
OPG, osteoprotegerin 
  
In order to uncover whether adipokines were deregulated in bone 
marrow fluid of HLs, the amount of protein was compared against donors’ 
marrow fluid. Table 6 presents the 10 most altered adipokines, overall, and 
within normal BMI and OW/OB groups. Notably, IGFBP-3 was down-expressed 
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independently of the obesity status, albeit other modulators of IGF axis were 
altered (IGFBP1, -13.2 fold). Circulating cytokines known to regulate 
inflammation, IL-8, IL-1a, IL-12 and IL-1b were all depressed in HLs’ marrow 
fluid compared with controls (from -4.5 to -7.8 fold decrease). Leptin, a hormone 
almost exclusively secreted by adipocytes, was also significantly decreased by -
12.6 fold. Other growth factors, TGF-β1 and FGF-6, together with 
osteoprotegerin were all lower in HLs when compared with donors’ marrow 
fluid. 
 
Table 6: Top-ranked 10 most altered proteins of interstitial marrow fluid of Hodgkin’s 
Lymphoma patients in the array analyses 
Protein name Description Fold change Adjusted P 
Hodgkin Lymphoma’s versus Controls 
All subjects 
IGFBP-1 IGF binding protein -13.2 0.0049 
Leptin Leptin -12.6 0.0276 
IL-8 Interleukin 8 -7.8 0.0029 
FGF-6 Fibroblast growth factor 6 -7.6 0.0535 
IL-1a Interleukin 1 alpha -6.6 0.0029 
IGFBP-3 IGF binding protein 3 -6.4 0.0026 
TGF- β1 Transforming growth factor beta 1 -5.2 0.0408 
IL-12 Interleukin 12 -4.8 0.0029 
IL-1b Interleukin 1 beta -4.5 0.0029 
OPG Osteoprotegerin -4.2 0.0029 
Normal weight 
FGF-6 Fibroblast growth factor 6 -21.3 0.0712 
IGFBP-1 IGF binding protein 1 -10.6 0.0925 
IL-8 Interleukin 8 -9.0 0.0329 
OPG Osteoprotegerin -6.8 0.0186 
IL-1a Interleukin 1 alpha -6.5 0.0540 
IL-12 Interleukin 12 -6.2 0.0186 
IGFBP-3 IGF binding protein 3 -5.0 0.0329 
IL-1b Interleukin 1 beta -4.6 0.0329 
IL-6 sR IL-6 soluble receptor -4.3 0.0186 
Fas/CD95 Fas ligand receptor -4.3 0.0186 
Overweight/obese 
IGFBP-3 IGF binding protein 3 -8.2 0.0300 
IGF, insulin growth factor;  
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 The comparison of utmost subgroups, between HLs simultaneously 
OW/OB (n=4) and controls having normal BMI (n=4), yielded a reinforcement of 
the potential IGF axis involvement in the association obesity-HL (Table 7). 
IGFBP-1, IGFBP-3 and IGFBP-2 were all significantly reduced in the marrow 
fluid of OW/OB subjects with HL. Furthermore, cytokines involved in 
inflammatory regulation (IL-8, IL-1b, IL-12 and MIP-1b) were also diminished in 
this group. 
 
Table 7: Altered proteins in interstitial marrow fluid of Hodgkin Lymphoma patients 
simultaneously overweight/obese compared with Controls that have normal BMI 
 
Validation of four of the most consistently deregulated adipokines in 
bone marrow fluid was done using ELISA experiments. Data was further 
adjusted to the amount of protein in IMF. In table 8, from 4 adipokines 
deregulated in the array, only IGFBP-3 remained significantly lower in IMF of HL 
patients in ELISA. 
 
Table 8: Concentrations of deregulated adipokines between pathology groups using 
ELISA 
 Control (n=8) HL (n=8) P-value 
Osteoprotegerin (pg/mL/µg) 0.10 ± 0.02 0.13 ± 0.04 0.600 
IGF binding protein 1 (ng/mL/µg) 0.06 ± 0.03 0.01 ± 0.004 0.345 
IGF binding protein 3 (ng/mL/µg) 0.18 ± 0.03 0.14 ± 0.06 0.046 
Interleukin 8 (pg/mL/µg) 0.09 ± 0.05 0.07 ± 0.02 0.401 
HL, Hodgkin’s Lymphoma; IGF, insulin growth factor. Results are presented as adipokine 
concentration adjusted per µg of total protein concentration in IMF 
 
When analyzed according to obesity groups (normal BMI versus 
Protein name Description Fold change Unadjusted P 
IGFBP-1 IGF binding protein 1 -14.6 0.0895 
IGFBP-3 IGF binding protein 3 -8.0 0.0341 
IL-8 Interleukin 8 -8.0 0.0895 
IL-1b Interleukin 1 beta -4.4 0.0895 
Fas/CD95 Fas ligand receptor -4.0 0.0820 
IL-12 Interleukin 12 -3.9 0.0895 
IGFBP-2 IGF binding protein 2 -3.2 0.0895 
MIP-1b/CCL4 Macrophage inflammatory protein-1β -1.9 0.0895 
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OB/OW), we observed that osteoprotegerin level in IMF, which was altered on 
the array, is not distinct between groups classified by BMI (Table 9).  
 
 
Table 9: Concentrations of deregulated adipokines between obesity groups using 
ELISA. 
 BMI (Kg.m-2)  
 < 25 (n=8) ≥ 25 (n=8) P-value 
Osteoprotegerin (pg/mL/µg) 0.12 ± 0.04 0.10 ± 0.02 0.916 
IGF binding protein 1 (ng/mL/µg) 0.05 ± 0.03 0.03 ± 0.01 0.401 
IGF binding protein 3 (ng/mL/µg) 0.20 ± 0.06 0.10 ± 0.02 0.208 
Interleukin 8 (pg/mL/µg) 0.10 ± 0.05 0.06 ± 0.02 0.753 
HL, Hodgkin’s Lymphoma; IGF, insulin growth factor. Results are presented as adipokine 




4.3. Correlative analyses of anthropometric measures and 
adipokine concentration in IMF and in circulation 
Once the validation step was concluded on the same samples (n=16) 
used in the array, we extended ELISA measurements to the additional IMF 
samples, rendering a whole population of 11 controls and 16 HLs. In this set of 
subjects we questioned whether BMI was associated with abdominal perimeter, 
a specific measure of central obesity. Spearman correlation coefficient analysis 
demonstrated a good agreement between BMI and waist measurements 

















Figure 5: Association between BMI and abdominal perimeter. 
BMI, body mass index. Spearman correlation coefficient. 
 
 Following this association between general and abdominal adiposity 
markers, we sought to examine the degree of correlation between central 
obesity and adipokines in IMF. We observed that the abdominal perimeter was 
inversely correlated with IGFBP-3 and with IGFBP-1 levels in IMF (r=-0.416, 
P=0.039 and r=-0.473, P=0.017, respectively), but no association was found for 
BMI (data not shown). 
 In HLs (n=16) we searched for an association between 
clinicopathological characteristics and IMF levels. The levels of adipokines were 
not related with histopathology subtypes, clinical staging and presence of B 
symptoms (data not shown), except for a strong trend towards lower IMF levels 
of IL-8 in patients with B symptoms (with symptoms, average 0.02±0.004 
pg/mL/µg, and without symptoms average 0.05±0.01 pg/mL/µg, P=0.052). 
 The level of concordance between IMF adipokine and circulating serum 
concentrations was assessed using Spearman correlation coefficient. Table 10 





Table 10: Evidence of good representativeness of adipokine IMF concentrations in 
serum from peripheral blood 
Conc. in IMF /µg protein  Conc. in serum/µg protein r * P-value 
Osteoprotegerin vs Osteoprotegerin 0.156 0.456 
IGF binding protein 1 vs IGF binding protein 1 0.630 0.001 
IGF binding protein 3 vs IGF binding protein 3 0.467 0.021 
Interleukin 8 vs Interleukin 8 0.419 0.037 
* Spearman correlation coefficient 
 
 A good correlation was found for adipokines levels in IMF versus serum, 
both using the concentrations adjusted for total protein (Table 10) and without 















The marrow stroma is a cellularly rich portion of bone, in which a broad 
range of signals emanates from the crosstalk between adipocytes, fibroblasts, 
osteocytes, hematopoietic stem cells and their progeny, endothelial cells and 
macrophages. We hypothesized that distinctive environmental factors may 
influence absolute and relative cellular quantities and influence the marrow 
microenvironment. This unbalanced microenvironment not only can support the 
attraction of tumor cells towards the marrow but also the maintenance of a 
specific environment for tumor growth. In addition, bone resorption and bone 
formation are likely to become affected. The more aggressive phenotype of 
disease for many primary tumors, including Hodgkin’s lymphoma (HL), is when 
malignant cells travel throughout the blood or lymphatic vessels until they are 
established and grow in the bone marrow [105]. In HL, an estimated 4 - 14% of 
patients will develop blastic bone metastasis, which represents a bad prognosis 
factor [106, 107]. 
It is expected that bone marrow characteristics would be noticeable in 
the fluid surrounding bone marrow cells, notably the assortment of locally- or 
systemically-produced adipokines in situations of excess adiposity with 
hypertrophied adipocytes. Current knowledge about the content of adipokines in 
the bone marrow fluid is practically unexplored in patients with cancer and/or 
with obesity.  
Concerning the association of BMI with HL risk, there are few studies 
that have addressed this issue. From the twelve prospective studies, 5 
identified risk for HL with an increase of 10kg/m2 of BMI or obesity. However, 2 
studies found a protective role for obesity in the development of HL. Despite the 
batch of positive association studies between obesity and HL, it is important to 
highlight the time when the anthropometric assessments were made and the 
outcomes considered. In fact, obesity may increase the risk for developing HL, 
even though its effects in survivors may be paradoxal, thus influencing the 
natural history of disease.  
BMI is an imperfect estimate of adiposity, thus to uncover the obesity-
cancer relationship, studies that assess adipokine profile may provide more 
accurate information. Using an adipokine membrane array, we sought to 
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characterize the bone marrow microenvironment concentrations of 62 
adipokines. In the IMF from both HL patients (prior to diagnosis) and controls, 
we compared their expression using overweight/obesity as primary outcome 
and presence of HL as secondary outcome. Analysis of altered adipokines in 
the IMF of HLs revealed that several pathways were down-regulated, 
specifically in IGF axis (IGFBP-1, IGFBP-2, IGFBP-3), cytokines involved in 
immuno-inflammatory response (Leptin, IL-8, IL-12, IL-1β, IL-1α, IL-6sR, 
Fas/Cd95, MIP-1b/CCL4), growth factors (TGF-β, FGF-6) and bone remodeling 
(OPG).  
When patients were stratified by BMI classification, we found that only 
osteoprotegerin (OPG) was significantly elevated in the IMF of OW/OB. 
Osteoprotegerin is a secreted glycoprotein member of TNF-alfa receptor 
superfamily, which acts in bone microenvironment as a decoy receptor, binding 
to RANKL-mediated osteoclast recruitment and activation. Therefore, the 
increased RANKL/OPG ratio is critical for osteoclastogenesis, by inhibiting 
osteoclasts differentiation and osteoclastic bone resorption [108]. Adipocytes, 
normal constituents at the bone marrow microenvironment, were reported to 
crosstalk with osteoblasts and increase RANKL while decreasing OPG 
secretion in the bone marrow, influencing RANKL/OPG ratio through a still 
unknown mechanism [109]. Previous data supports a reduced level of OPG and 
increased RANKL in the bone marrow of obese mice, which was correlated with 
higher marrow adiposity and upregulated osteoclastogenesis [69, 73]. In 
agreement, a report revealed higher OPG levels in the IMF of osteoporotic and 
leaner women [110]. Conversely, in our study OPG concentration was 
significantly higher in the IMF of OW/OB by 2.5-fold overall and by 4-fold in 
OW/OB with HL compared with lean HLs. When compared between HLs and 
controls the expression of OPG in IMF was significantly down regulated by 4- to 
7-fold. These findings may reflect a systemic influence of the environment either 
modulated systemically by the tumor itself or through paracrine and/or 
endocrine mediators from adipocytes and adipose tissue. It is well established 
that OPG is secreted primarily by osteoblasts but also by adipocytes [111]. In 
conditions of excess adiposity, some reports mentioned increased marrow 
adipocyte count and hyperthrophy [112]. The mechanism involves PPARγ-
mediated preferential mesenchymal stem cell differentiation into adipocytes 
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while simultaneously inhibiting osteogenesis [73]. This guidance towards 
adipogenesis induced by excess adiposity might also be responsible for the 
upregulation of OPG secretion in the bone marrow, particularly through leptin, 
which has been shown to influence OPG production. The increased disposal of 
OPG in OW/OB’s marrow is likely to decrease RANKL bioavailability, and 
subsequently reduce osteoclastogenesis. This reduction may account for 
decreased bone resorption and release of growth factors and calcium [108, 
113, 114], concurring towards a suppressive effect on metastasized tumor cell 
growth.  
HL has a unique pathological feature characterized by a minority of 
malignant H-RS (0.1 - 1%) able to express receptors of a variety of 
cytokines/chemokines [115]. The cytokine network in HL-affected tissues has 
been described to be important not only for autocrine proliferative stimulus on 
HRS cells, but also for the maintenance of a favorable environment. ILs (e.g., 
IL-1α, IL-3, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13), chemokines (thymus- and 
activation-regulated chemokine CCL17, TARC, CCL22, MDC), M-CSF, TNF-α, 
TGF-β, soluble CD30 and chitinase-3-like protein 1 (YKL-40) are among the 
many cytokines that are expressed and influence the survival of HRS cells [18, 
19, 29, 103]. 
Under this scenario, we found lower levels of IL-1a, IL-1b, IL-8 and IL-12 
in interstitial marrow fluid of patients with HL. The mechanisms of immune 
escape of HRS cells are notable, preventing them from toxicity by inhibiting 
cytotoxic T and NK cells, as well as promoting Treg and Th2 cells [10, 115]. 
Other immune escape mechanisms include the overexpression of FAS ligand 
(CD95L), a member of the TNF receptor family, which plays a key role in 
promoting programmed cell death (apoptosis) and is activated by its ligand Fas-
ligand (FasL), inducing apoptosis in cytotoxic T lymphocytes and the loss of 
expression of HLA class I and II molecules [116]. So, the down-expression of 
CD95 (both in HL normal weight and overweight / obese) allows an anti-
apoptotic mechanism of the CD95+ cytotoxic T cells. 
The low-grade chronic inflammation characteristic of obesity also 
represents a contribution to immunomodulation. Accumulated macrophages in 
adipose tissue are thought to be responsible for the obesity-induced 
inflammation and their infiltration is strongly correlated with body mass index 
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and total body fat. There, these recruited macrophages express high levels of 
inflammatory factors contributing to systemic inflammation and insulin 
resistance [117], including IL-12, IL-23, TNF-α, iNOS and MHCI/II. In 
inflammatory microenvironments, as in tumors, the macrophage inflammatory 
protein 1 alfa (MIP-1a) and 1 beta (MIP-1b) are potent chemoattractants for 
monocytes, contributing to the recruitment of this important component of of 
tumor tissue stroma [118]. Therefore, the reduced expression of MIP-1b/CCL4 
in HL OW/OB subjects may influence the quality and quantity of immune-cell 
infiltration and, consequently, a non-proliferative milieu for HRS cells. Indeed, 
the production of CCR5 ligands (CCL5, CCL3 and CCL4) by stromal cells has 
been identified to contribute to H-RS cells proliferation [119].  
Hitherto, the obesity-associated immunoinflammatory mechanisms 
suggest an unfavorable microenvironment for the growth of HRS cells in the 
bone marrow. Concordantly, we observed that pro-inflammatory adipokines, IL-
8, IL-1β and IL-12 were also underexpressed independently of obesity status. 
Data from previous studies suggest that increased serum cytokines associate 
with disease relapse and inferior survival in HL [18, 19, 103], although the 
specificity of bone marrow microenvironment [120] may alter this profile, 
implicating adipocytes as negative regulators of the bone-marrow 
microenvironment, as previously reported [21]. IL-12 has anti-tumoral effects, 
such as differentiation of T helper cells type 1 (Th1) cells, stimulation of 
interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production, 
enhancement of natural killer (NK) cell’s cytotoxic activity, and anti-angiogenic 
activity. Furthermore, the macrophages associated with tumors produce IL-10, 
suppressing IL-12 expression, which favors tumor escape from immune 
surveillance [121]. Thus, the decreased expression of IL-12 in the IMF of HL 
patients is likely to represent a negative microenvironment for the settlement of 
HL metastatic cells. Another proinflammatory adipokine is IL-1β, which was 
observed here to be down-regulated, therefore contributing to attenuated 
metastasis via modulation of activator protein 1 (AP-1) and nuclear factor – IL6 
(NF-IL6) [122].  
Moreover, the bone modulation through the over-expression of OPG in 
HL overweight / obese, which induces a disruption of RANKL/RANK autocrine 
loop, influences the expression of IL-8 [113], committing the typical neutrophil 
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infiltration on HL microenvironment. Analyzing only in the association of HL 
clinicopathological characteristics with adipokines levels in the IMF, just IL-8 
was border (p = 0.052) associated with B symptoms, contrary to previous 
reported in serum [103]. 
In the context of the association bone marrow-adipocytes, we found the 
hormone leptin was significantly lower in interstitial marrow fluid of HL patients. 
Leptin is one of the most important adipokines, with a well-described role in the 
regulation of obesity in the central nervous system, although its peripheral 
actions remain incompletely understood. In the bone marrow, its receptor 
(LepR)-expressing mesenchymal stromal cells are the major source of bone 
and adipocytes in adult bone marrow [123]. In addition, leptin favors 
osteogenesis [124]. Previous studies, reported that serum leptin levels were 
negatively correlated with international prognostic score (IPS) in HL [102], 
whereas in the present study bone marrow leptin levels significant decreased –
by 12.6-fold in HLs. Taken together, these findings suggest that while increased 
circulating leptin correlates with better clinical prognosis, the decreased leptin in 
the bone marrow might reflect a protective effect for colonization by malignant 
cells. Indeed, the role of leptin in the promotion of hematologic tumorigenesis 
through activation of the PI3K/Akt, ERK and/or Jak2/STAT3 pathways, have 
been described [125]. Interestingly, the simultaneous downregulation of OPG 
and Leptin we observed, may underline the crosstalk between bone and fat, 
namely an activation of bone resorption. 
Growth factors have been described as inducers of growth and survival 
of malignant cells, and as intervenients in tumor cell dissemination [126]. In HL, 
the Treg and H-RS cells produce IL-10 and TGF-β, exerting inhibitory effects on 
T-cell effector functions, especially on cytotoxic T lymphocytes (CTLs) [127]. 
Thus, as we noticed, and according to others, the underexpression of growth 
factors such as TGF- β and FGF-6 in HL may confer protection to establishment 
of metastasis [128]. 
The IGF axis has been one of the most extensively implicated pathways 
in obesity-cancer association. The onset of insulin resistance and 
compensatory hyperinsulinemia during obesity may explain cancer promotion 
by stimulating cell proliferation and inhibiting apoptosis through IGF-IR-
mediated signaling mechanisms [129]. Elevated insulin levels lead to increased 
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bioavailable IGF-I, being synthesized and secreted by the liver and other 
organs, as well as, by tumors.  
Besides its autocrine and paracrine actions, IGF enters the bloodstream 
and binds to specific proteins to form binary complexes with each of the six IGF 
binding proteins (IGFBPs).  
IGF-I has been described to have a special relevance in shaping and 
sustaining the microenvironment of HL. IGF-1 expression has been 
demonstrated in HL, by the cells composing the microenvironment and by 
tumor cells, whereas its receptor (IGF-1R) immunoreactivity varied in H-RS 
cells [129]. Thus, while IGF-1 is produced by the tumor microenvironment and 
H-RS cells express the IGF-1R, we observed a down-regulation of IGBPs 
(IGFBP-1, IGFBP-2 and IGFBP-3). Together, these findings will likely result in 
increased free IGF-1 availability in the bone marrow, upregulating ligand-
receptor activation in H-RS cells. Despite the activation of IGF-1/IGF-1R in HL 
cell lines was oncogenic, the upregulation of IGF-axis has been reported to be a 
significant predictor of a favorable outcome [130, 131]. While the explanation for 
these findings remains unknown, new research endeavours should focus on the 
resulting crosstalk between HL malignant cells and tumor microenvironment 
players, including adipocytes. 
Interestingly, IGFBP-1 and IGFBP-3 in bone marrow were well correlated 
with serum, and were found to be inversely associated with abdominal 
perimeter, but not with BMI, even though BMI and abdominal perimeter were 
strongly correlated. Therefore, regional depots of adipose tissue (visceral 
adiposity) may have a stronger influence on distant microenvironment and be a 
better marker for obesity-associated HL. 
Although we present novel data on the characterization of adipokine 
profile in IMF of obese and HL subjects, and identify the most relevant 
biological axes behind the relationship between obesity and HL, our results 
should be interpreted in the context of several potential limitations. The reduced 
sample size, particularly for validation of adipokines in IMF and for the 
correlation with peripheral blood levels, advises cautious interpretation of data, 
even though Hodgkin’s lymphoma is a rare haematological malignancy. The 
estimated adipokine quantification has had an exploratory intent, without having 
the opportunity to validate our findings in a completely new and separate set of 
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patients and controls. Nevertheless, selection of patients and controls to include 
in the array was carefully age-, BMI-, and gender-matched, in order to minimize 
group heterogeneity. Therefore, further studies in IMF from independent 
populations and with utmost BMI phenotypes are required. Our OW/OB 
population was mostly composed of OW subjects (BMI, 25-30 Kg/m2). Use of 
additional and more sensitive methods to evaluate adiposity (e.g. bioimpedance 
analysis, DEXA, visceral adiposity using CT scan) would yield a better 
stratification of excess adiposity for array analyses. 
Once in our population no HL patients were positive for bone metastasis, 
we were unable to test further the hypothesis of bone marrow microenvironment 
response to the presence of tumor cells. The continued accrual of samples from 
patients and controls will likely result in added bone marrow samples from 
patients with bone metastasis. Then, a retrospective comparative analysis can 
be performed with present results in IMF from negative-bone metastasis HL 
patients. 
Overall, the bone marrow microenvironment in HL may play a role 
allowing the H-RS cells to survive, by providing an environment that suppresses 
cytotoxic immune responses. This exploratory study, identified that 
underexpressed adipokine pathways in the bone marrow are likely modulators 
of immunoinflammatory (Fas/CD95, IL-12, IL-1 β, IL-8, MIP-1b/CCL4), 
hormonal (leptin), proliferative (TGF-β, FGF-6 and IGF-axis binding proteins, 
IGFBP-1, IGFBP-2, IGFBP-3) mechanisms, which ultimately convey protection 
to the establishment of metastatic disease in HL. Furthermore, the adipocyte-
bone crosstalk, represented by leptin and OPG interaction, are likely to impact 





















This study addressed the causal association of obesity and Hodgkin's 
lymphoma (HL) from the perspective of bone marrow microenvironment. Its 
exploratory nature in a rare biological sample prompted the use of a protein 
screening array, which simultaneously analyzed 62 adipokines in a specific 
environment as the bone marrow fluid.  
Overall, findings from this study agree with a very limited number of 
reports on obesity as a good prognostic factor for HL, albeit in contrast with the 
established evidence of obesity as risk factor for developing HL. Taken 
together, the low pro-inflammatory profile, together with decreased growth 
factors and leptin, and with upregulated IGF-axis activation, we found in the 
bone marrow of obese HL patients are key characteristics of an unfavorable 
environment for metastatic seeding. In obesity, we expect to unveil that these 
adipokines are produced by adipocytes in bone marrow and to demonstrate 
they may interfere with metastatic HL microenvironment. This potential 
protective effect of obesity on bone marrow microenvironment of HLs applies 
exclusively to prognosis, rendering obesity-Hodgkin Lymphoma association 
another paradoxical case of obesity protective influence in cancer. 
In order to increase the precision of assessment of obesity-HL causal 
relationship, here we propose that stronger evidence would emanate from using 





















7. FUTURE PERSPECTIVES 
 
The exploratory nature of present work and the contour of results, urges for 
continuing the recruitment and accrual of bone marrow samples from HLs and 
donnors. This will allow, primarily an independent validation of results and then, 
because of higher probability to include metastatic patients, to study a group of 
patients with bone metastasis. Measurement of adipokines in the bone marrow 
of this group will contribute to uncovering the resulting effect of the crosstalk in 
marrow microenvironment that includes H-RS cells. 
In order to understand with higher precision the effect of obesity in HL, 
future studies that include patients should use more sensitive and specific 
methods for measuring adiposity (DEXA, bioimpedance, CT scan, …), both 
from local and general perspectives. As for HL risk, the impact of obesity in HL 
prognosis warrants further research, requiring the need to follow-up patients 
using more adequate adiposity measurements. 
Following the characterization of adipokine’s profile in the bone marrow fluid 
of HL patients and/or obese, the ensuing step will be to ascertain which cell 
population, marrow adipocytes or stromal cells, is responsible for the altered 
expression of studied adipokines.  
In parallel, in vitro studies using the HL cell line L428, should be undertaken 
to evaluate the impact of recombinant adipokines, which were previously shown 
to be deregulated, in cancer hallmarks (e.g., proliferation, apoptosis, invasion, 
motility, …). Furthermore, using dataset from a retrospective HLs’ cohort that 
includes paraffin-embedded matched primary and metastatic HL tumors, will 
allow clinical validation of altered adipokine pathways. 
In a larger population, we expect to determine a multilocus genetic risk 
score from altered adipokine pathways in HL, to improve risk prediction and 
prognosis in a continuously increasing population of obese subjects. This risk 
score should include besides genetic markers, other demographic and 
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A solid body of knowledge indicates that overweight and obese subjects are 
more prone to have cancer, aggressive disease and death than their lean counterparts. 
Even though obesity has been causally associated with many cancers, only few studies 
looked for the link with Hodgkin’s Lymphoma (HL). Recent findings from meta-
analysis and prospective studies demonstrated an increased risk for subjects with higher 
body mass index to develop HL. Underlying epidemiological evidence, it is known that 
excess adiposity correlates with increased production of pro-tumoral and pro-angiogenic 
adipokines and is characterized by a chronic inflammatory state. Since inflammation is 
a cornerstone in HL development (pathophysiology) and aggressiveness, the role of 
adipose tissue, either through endocrine or paracrine mechanisms and both at its 
primary site and in bone marrow, must be of importance. 
In this hypothesis generating review we explore the association between excess 
adiposity and HL, in light of recent basic and clinical data, to create a basis for 
understanding the mechanisms that underlie this epidemiological association, and to 
untangle hazy routes, fostering applied research. The establishment of excess adiposity 
as a significant risk factor for HL will determine public health preventive measures to 











Obesity has been described as a cause of morbidity and mortality and it is 
estimated that the number of deaths caused by cancer will double by 2030, as a result of 
the obesity epidemic [1]. The association between obesity and many cancer types has 
been consistently established [2]. In Hodgkin’s Lymphoma (HL), despite an apparently 
variable association with overweight and obesity (according to the body mass index-
based World Health Organization classification) [3-7], a contemporary meta-analysis on 
prospective studies established a significant association between body mass index 
(BMI) and risk for HL [8]. Concordantly, a new prospective study in over 1 million 
individuals demonstrated increased risk for HL development for each 10 Kg.m-2 units of 
increase in BMI [9]. Although epidemiologically obesity seems to be associated with 
HL, the biological rationale and mechanisms behind this causal relation remain largely 
unexplained. 
Hodgkin’s Lymphoma is characterized by an inflammatory microenvironment at 
the lymph nodes primary tumor site [10, 11]. The distinctive HL’s malignant Hodgkin 
& Reed-Sternberg (HRS) cells reciprocally interact with the inflammatory milieu 
resulting in tumors with survival and evasion advantages [10]. Besides age, 
inflammation and Epstein-Barr virus (EBV), little is known concerning predictive 
factors of HL aggressiveness [12, 13]. Noteworthy, despite the high cure rate, in 
advanced stage disease approximately 25% to 30% of patients are not cured with 
standard therapeutic regimens alone, and about 20% of the patients still die after relapse 
or disease progression [12, 14]. In advanced stages, where bone marrow infiltration is 
common, the international prognostic score and other risk stratification instruments 
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remain only modestly effective to predict disease progression and therapeutic response 
[15].  
Excess adiposity is regarded as a chronic inflammatory state, hence excess 
adiposity-mediated inflammation may play a role in promoting HL growth, survival and 
tumor immune evasion [10]. We hypothesize that this accumulation of immune cells in 
HL, including T and B cells, neutrophils, eosinophils, and mast cells might be disturbed 
by excess adiposity, which is known to modulate the immune system function [16, 17]. 
In addition to immunoinflammatory derangements, there is a systemic metabolic 
dysfunction in obesity that prompts altered circulating levels of pro-tumoral adipokines. 
Indeed, some of these adipokines have been associated with HL and advanced stages of 
disease [18-20]. Albeit the mechanisms of the causally invoked association between 
obesity and HL remain undetermined, a reasonable biological rationale supports 
plausibility for the relation of adipose tissue-inflammation-HRS axis with HL 
aggressiveness. Taken together these obesity-linked endocrine and paracrine 
mechanisms may create a favourable microenvironment for growth and spread of HRS 
malignant cells. Moreover, albeit still experimentally unproven, it is expected that the 
known paracrine action of adipocytes in the bone marrow microenvironment [21, 22] 
might facilitate HRS cells to metastasize and grow within the bone marrow 
microenvironment. 
Future research should establish definite biological mechanisms involved in the 
association between excess adiposity and HL, which will foster the development of new 
molecular markers based on adipokine’s pathways as indicators of clinical outcome and 
incorporated into prediction models. If confirmed, the effects of bone marrow 
adipocytes in metastatic HL cells might represent new potential therapeutic targets in 




MECHANISMS PROMOTING HODGKIN LYMPHOMA’S: LESSONS TO 
ESTABLISH NEW DRIVERS 
 
HRS cells, despite their small representativeness in HLs (about 1%), are 
modulated by a mixed inflammatory microenvironment that influences tumor 
development [10, 23]. These unique features of HL are far outweighed by reactive and 
stromal cells [10]. Inflammation, among others, has been recently considered as a 
cancer hallmark [24]. In fact, survival, proliferation and immunoinflammatory 
mechanisms seem to have an important role in HL pathophysiology [10].  
The HL tumor microenvironment, in particular, the cytokine/chemokine pattern 
secreted by HRS cells and non-neoplastic circulating cells may influence the 
proliferation and survival of malignant cells [25, 26]. Among others, HRS cells secrete 
several interleukins (ILs) (e.g., IL-1α, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IL-13), 
chemokines (CCL17, TARC, CCL22, MDC), macrophage colony stimulating factor 
(M-CSF), tumor necrosis factor-α (TNF-α) and β (TNF-β), transforming growth factor 
beta (TGF-β), soluble CD30 and chitinase-3-like protein 1 (YKL-40), with autocrine 
tumor growth effect [25]. From these molecules, thymus and activation-regulated 
chemokine (TARC) and macrophage-derived chemokine (MDC), produced by HRS 
cells, are partially responsible for whittling HL microenvironment by inducing Th2 and 
Treg cell responses [25], which by exerting anti-inflammatory and immunosuppressive 
activities, have been associated with reduced tumor immunosurveillance [27]. 
Moreover, paracrine actions were uncovered through upregulated pathways mediated by 
cytokine receptors (IL-2R, IL-6R, IL-9R, IL3R), macrophage colony-stimulating factor 
receptor (M-CSFR), tumor necrosis factor receptors (TNFR1, TNFR2), CD30 and 
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CD40 [28]. As an example, downstream signalling through the IL-3/IL3R pathway 
induces growth and extends survival in HL cells [29]. Paracrine signals may arise from 
non-malignant tumor-infiltrating cells in HL microenvironment (e.g., eosinophils, mast 
cells, neutrophils and macrophages) [10]. The nuclear factor-kappa B (NF-kB) and 
Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathways 
have been identified as important modulators in HL [26]. Activation of the NF-kB 
pathway, which is involved in the expression of multiple anti-apoptotic factors and pro-
inflammatory cytokines, reduces the expression of CD99, a marker associated with 
HRS cells phenotype [10]. This cell surface receptor is involved in Tcell adhesion, 
leukocyte  migration, and Tcell caspase-independent cell death, playing also a role in 
the induction on human thymocytes of Tcell receptor (TCR) and Major 
histocompatibility complex Class I and II molecules expression. It has been reported 
that CD99 deficiency leads to the arrest of MHC Class I molecules at the Golgi 
complex, impairing their transport to the cell surface, which constitutes one of the most 
frequent immune escape mechanisms adopted by cancer cells [132]..Some authors 
identified candidate-circulating biomarkers for HL, with prognostic and/or predictive 
response to therapy values. These molecules act at HL site and modulate disease 
outcome [30-32]. Furthermore, it was found that before treatment, HL patients have 
increased levels of serum interleukin 6 (IL-6) and YKL-40, both facts correlated with 
disease progression stage [18].  
 
OBESITY AND HODGKIN LYMPHOMA 
 
Obesity is currently considered epidemic worldwide [33]. Overweight and 
obesity are defined as excessive accumulation of adipose tissue and are associated with 
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increased risk of morbidity and premature mortality. Besides other related diseases, 
epidemiological studies reported obesity as a risk factor for cancer [2, 34, 35]. In the 
United States of America the estimated risk of death from cancer in morbidly obese 
(BMI ≥ 40 kg/m2) was 1.5 in men and 1.6 in women [34], whereas in Europe, obese 
have 1.5 to 3.5 higher risk of having cancer [1]. Alongside, it has been estimated that 
approximately 30% of cancer deaths might be related with dietary and behavioural 
factors, namely, high BMI, low intake of fruits and vegetables, lack of exercise, 
smoking and alcohol abuse. A recent meta-analysis based on prospective studies 
reported that obesity (BMI ≥ 30 kg/m2) are positively correlated with risk of HL [8]. 
Indeed, a number of studies reported a positive association of obesity with hematologic 
malignancies, including Hodgkin’s lymphoma [3-7, 9, 35], even though others have not 
found such an association [36-42]. Noteworthy, 2 studies found a protective role for 
obesity in the development of HL. Despite the batch of positive association studies 
between obesity and HL, it is important to highlight the time when the anthropometric 
assessments were made and the outcomes considered. Indeed, some authors consider 
that this potential protective effect of lower BMI in cancer may be due to the effects of 
cancer-related cachexia, a more deleterious than the potential adverse events related to a 
higher BMI [131]. Obesity may increase the risk for developing HL, even though its 
effects in survivors might be paradoxal, thus influencing the natural history of disease 
[130].  
Specifically in HL, the intake of saturated fats, which is also related with excess 
adiposity, can modulate the immune function through an anti-apoptotic action on T cells 
and increased expression of pro-inflammatory molecules [133]. Nevertheless, most 
studies rely on body mass index measures and World Health Organization BMI-based 
classification of obesity, which are imperfect estimates of adiposity and disease risk 
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[44-46], and do not account for local fat depots (e.g., visceral adipose tissue), which 
were shown to have adverse specific adipokine expression profiles, contributing 
towards more aggressive tumors [47-49]. Future epidemiological studies should address 
these issues by using more precise methods (e.g. visceral and subcutaneous fat 
determinations by computed tomography scan, whole body fatness by tetrapolar 
bioimpedance, or local and whole body fat measurements through magnetic resonance 
imaging, among others) to evaluate whole and local body fatness in association with 
HL.  
Presently, the adipocyte is no longer considered a passive component of the 
human metabolism. It is known as an endocrine/paracrine c that exerts many biological 
effects, through production of growth factors, cytokines, chemokines and hormones 
[50]. These biologically active molecules secreted primarily, partially or exclusively by 
adipocytes, known as adipokines, have a significant role in regulating tissue 
angiogenesis and tumour growth [51]. In fact, the importance of the interaction between 
cancer cells and the surrounding stroma cells has been increasingly accepted. These 
interactions are particularly prominent in environments rich in adipocytes [52]. The 
excess body fatness is characterized by a chronic low-grade inflammatory state with 
altered circulating levels of adipokines, including IL-6, IL-8, leptin, adiponectin, TNF-
α, vascular endothelial growth factor (VEGF), osteopontin (OPN), haptoglobin (Hp), 
YKL-40, among others [53-55] (Figure 1). These molecules impact cancer cell-related 
mechanisms such as proliferation, apoptosis and migration [56, 57]. The altered 
secretion of adipokines in obesity deranges metabolic homeostasis, together with 
influences in immunological status [58] (Figure 1). In this context, the evaluation of 
markers related to obesity and immune response in HL, might reveal new opportunities 
for understanding the mechanisms responsible by the association between obesity and 
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HL. Various adipokines have already been shown to be linked with HL risk and with 
advanced stage of disease, namely IL-6 and interleukin 7 (IL-7) [18, 19, 59], while 
others endure as promising targets for future studies (e.g., leptin, adiponectin, resistin, 
HGF, visfatin, …). Thus, the chronic inflammation sustained by expanding adipose 
tissue may modulate the host immunosurveillance [16] and exert a direct effect on both 
the local tumor microenvironment and on distant tumor cells, through the systemic 
effects of paracrine signals (Figure 1). 
Angiogenesis is a well-established hallmark of tumor development both in solid 
tumours and hematological malignancies (including HL). Reasonable data, mostly 
supported by retrospective immunohistochemistry evaluations, stands for a relevant role 
of angiogenesis in HL. In this pathology, a shift towards an angiogenic phenotype is 
observed as result of unbalanced angiogenic versus anti-angiogenic stimulus [60]. 
Interestingly, many of the adipokines overexpressed by adipose tissue in obesity 
individuals are well-known for their potent pro-angiogenic effects [53]- Therefore, it 
seems plausible that these adipokines might mediate the causally invoked association 
between excess adiposity and HL, through a modulatory effect in angiogenesis (Figure 
1). 
Besides adipokine secretion, the expanding adipose tissue is also infiltrated by 
macrophages ongoing M2-to-M1 differentiation, further contributing towards the 
obesity-associated systemic chronic inflammation and insulin resistance [58, 61] 
(Figure 1). Leptin and adiponectin, hormones exclusively produced by adipocytes, and 
with opposing effects in obesity and cancer, contribute to the polarization of 
macrophages with a pro-inflammatory phenotype [62] and towards anti-inflammatory 
M2 [63], respectively. Interestingly, in HLs the presence of CD68+ tumor-associated 
macrophages indicates poor prognosis [23, 64] and higher adiponectin levels were 
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found in paediatric HL patients [65]. Recently, the soluble circulating CD163 and 
TARC were identified as possible biomarkers of HL [30]. Also interestingly, CD163 is 
a known marker for M2 macrophages polarization and a receptor for Hp, which is a 
major acute phase protein overexpressed in conditions such as obesity and HL [66, 67]. 
Nonetheless, Hp is induced not only by HL-associated IL-6 downstream transcription 
factor STAT3, but also by hypoxia-inducible factor-1α (HIF-1α) that is overexpressed 
in HL [68]. Therefore, excess adiposity seems to interfere with tumor cell’s signalling 
pathways and to modulate macrophages differentiation, both of which may impact the 
tumor. This obesity-driven inflammatory environment exerts tumor-promoting effects, 
due to alter inflammation pathways implicated in cell proliferation, survival, 
angiogenesis, and metastasis associated with cancer (Figure 1). Taken together, these 
evidences demonstrate potential unrevealed links that should foster experimental 
validation in order to uncover the impact of these obesity-associated molecules in HL. 
 
BONE MARROW ADIPOSITY AND HODGKIN LYMPHOMA - BONE MARROW 
ADIPOCYTES HAVE A ROLE IN METASTATIC NICHE?  
 
Adipocytes in the bone marrow have been implicated as regulators of marrow 
microenvironment [21, 69], and present a distinctive phenotype, which resembles both, 
white and brown adipose tissue [70]. Besides representativeness, bone marrow 
adipocytes present an unilocular lipid morphology similar to adipose tissue, and are a 
unique adipose depot that overexpresses genes associated with cell differentiation and 
with inflammation [71, 72]. Amplified bone marrow adiposity, due to diet-induced 
obesity in mice, was recently implicated in altered bone metabolism, and inflammation 
within the bone microenvironment [73]. Adiposity in bone marrow is modulated by 
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high fat diet, diabetes, aging, dyslipidemia and obesity, through diverse pathways that 
comes together to regulate the expression and activity of a key pro-adipogenic 
transcription factor, the peroxisome proliferator-activated receptor γ2 (PPAR-γ2) [74].  
Bone marrow adipocytes behave as energy suppliers to bone physiological 
functions, including bone remodelling [69, 75]. In addition to energy storage, these 
adipocytes secrete adipokines and fatty acids that impact significantly on metabolism 
and function of other neighboring cells, present within the bone microenvironment [72, 
76]. From this interaction in bone marrow milieu, an inverse relationship has been 
described between osteoblastogenesis and adipogenesis, with a negative correlation of 
marrow adiposity with osteoblast number and bone mineral density [74]. In fact, several 
factors produced in the bone marrow may exert a regulatory role in local adipocytes, as 
well as adipokines secreted in marrow adipocytes might influence other cellular players 
through a paracrine effect [76] (Figure 2).  
Hodgkin’s lymphoma involving the bone marrow ranges between 2 to 32%, 
with an average incidence of 10% [77]. Although the chronic low-grade inflammation 
and the upregulated secretory profile, associated with obesity, may exert endocrine 
effects, we should not overlook paracrine actions of adipocytes in bone marrow 
microenvironment bearing metastasis from primary HL tumors [22]. The crosstalk 
between adipocytes and cancer cells has been demonstrated to support progression and 
aggressiveness of tumors in other oncologic models [52, 78-80], as well as metastatic 
cell growth in the bone marrow [81]. Fat cells seem to be able of translocating stored 
lipids to metastatic tumor cells, ultimately driving cancer growth and motility [78, 82]. 
The complex interaction between components of bone marrow, including adipocytes 
and eventually tumor cells, is depicted in Figure 2.  
In other oncologic models, the fatty acid binding protein 4 (FABP4) was 
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implicated in adipocyte-tumor cell interactions [78, 81]. Notwithstanding FABP4 is 
transcriptionally regulated by PPARγ, this lipid chaperone also controls PPARγ [83, 
84], while both seem to be involved in adipocyte-induced metabolic switching with the 
in cancer microenvironment. Interestingly, in B lymphoma cells the decreased PPARγ 
expression was related with increased proliferation and survival, and initiation of 
inflammatory pathways, specifically the activation of nuclear factor kappa B (NFκB) 
[85], further underline the link between cellular metabolism and neoplastic progression. 
Primary cancer-derived metastases that home to the bone are by themselves 
incapable of inducing bone resorption. However, these aggressive malignant cells 
interact with bone constituents and influence the function of bone-degrading cells 
(osteoclasts), inducing osteolytic lesions [86]. Bone metastases from HLs have been 
described as osteolytic [87, 88]. The complex interaction of tumor cells with bone 
marrow microenvironment, including adipocytes, exerts profound influence in 
proteolytic degradation and bone resorption, enabling metastasis allocation. Obesity and 
aging are known effectors of bone remodelling by forming adipocytes instead of 
osteoblasts, which will lead to increased osteoclast activity and osteoporosis [76, 89]. A 
key enzyme for bone matrix osteoclastic bone resorption is cathepsin K (CTK) that 
degrades the bone matrix protein collagen I and other proteins of the [90]. CTK 
expression within the bone marrow milieu is high in osteoclasts and adipocytes, and 
results in accelerated bone turnover [91] and in a potential contribution to the metastatic 
process. CTK production was also described in cancer cells that metastasize to bone 
[92]. CTK acts by upregulating the processing of its substracts extracellularly, including 
the secreted protein acidic and rich in cysteine (SPARC or osteonectin) that interacts 
with collagen I and other matrix proteins to attract and anchor malignant cells in the 
bone [91]. In addition, VEGF, a growth factor known to be involved in tumor cell 
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migration and in osteoclast differentiation and migration has been proposed to be 
modulated in the bone microenvironment by CTK cleavage [90, 93]. Besides the key 
role of CTK in degrading collagen I, it also seems to be relevant for adiponectin 
cleavage, which may be a mechanism to promote osteoclastogenesis via increased 
expression of receptor activator of NFκB ligand (RANKL), to modulate marrow 
fatness, or to influence adiponectin-mediated suppression of tumorigenesis [94, 95]. On 
their tutone marrow adipocytes also stimulate osteoclast differentiation and activity by 
directly secreting RANKL [96].  
Bone marrow adipocytes are a significant secondary source of leptin and IL-6, 
whereas only trace amounts of IL-1β and TNF-α were found [97]. These molecules 
exert interactive regulatory mechanisms between them, in order to modulate the marrow 
environment, controlling the proliferation and differentiation of hematopoietic 
precursors as well as the maturation of stromal cells [98].  
Given the importance of JAK/STAT signalling in HL malignant cells and that 
leptin and IL-6 downstream signals are mediated by this pathway [99, 100], we 
hypothesize that these adipokines might influence HRS cell survival and proliferation, 
both through an endocrine mechanism in lymph nodes and by a paracrine effect in the 
bone marrow. Since leptin and IL-6 are upregulated in the serum of obese subjects, they 
can partially explain the association between excess adiposity and HL. Only few 
unpowered studies have measured serum leptin and adiponectin levels in HL patients, 
mostly children, with inconclusive mixed results [65, 101, 102]. With respect to IL-6, 
several reports demonstrated that it was a relevant cytokine for HRS proliferation and 
survival and a useful biomarker of aggressiveness [103, 104]. It is largely unknown 
whether bone marrow adipocytes behave differently in presence of HL malignant cells. 
Thus, further investigation on the interactions of bone marrow adipocytes with HRS 
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cells is required to clarify many unanswered questions and advance knowledge with 
potential clinical translation. 
Here, we hypothesize that when HRS cells are metastasized to bone marrow, resident 
adipocytes may have a role in bone remodelling, yielding tumor cells with adipokines 
and fatty acids to boost growth and survival, concurring towards worst prognosis. 
Further clinical studies should follow disease behaviour in HL obese patients and 
evaluate the impact of intervening in obesity on HL prognosis. Therefore, obesity and 





Obese subjects are at increased risk of progression of certain cancers, as seems 
to be the case of HL. Knowledge of adipocyte biology in the context of malignancy is 
therefore crucial for understanding the pathophysiological basis of obesity associated 
HL. The excess adiposity setting provides a unique microenvironment with concomitant 
systemic endocrine alterations that may,  by affecting cancer cell activities or by 
impairing tumour immunosurveillance, favor tumor progression [134]. The 
reprogrammed tumor-educated behavior of adipocytes likely provides a tumor-
permissive metabolic, inflammatory, fibrotic and angiogenic microenvironment that 
promote both primary and metastatic HRS cells survival. Therefore, understanding the 
heterotypic interactions between adipocytes and HRS cells could lead to the 
identification of further novel targets for HL therapy.  
Although intuitively relevant for future studies, the effects of lifestyle 
intervention in HL prevention and treatment are not yet clear. The impact of these 
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interventions on weight loss also offers a means for testing the reversibility of some 
mechanisms triggered by obesity. Thus, research endeavour to ascertain the influence of 
weight loss and other lifestyle changes (e.g. physical exercise or diet) on HL risk or 
outcomes is both required and feasible. Randomized controlled trials including physical 
exercise, nutrition or both interventions are urgently needed to guide recommendations 
for susceptible groups and for HL survivors, and to support implementation of 
chemoprevention strategies and weight management programs. Indeed, the Clinician-
patient relationship after cancer diagnosis is an opportunity to encourage lifestyle 
modifications, which might impact cancer recurrence, risk of other diseases and overall 
quality and length of life [135].  
Targeting adipose tissue with anti-obesity and/or antidiabetic agents, such as 
metformin and thiazolidinediones, might be a promising option to treat patients with 
cancer who are overweight or have obesity. However, despite metformin is highly 
active against cancer growth, so far there are neither experimental studies nor clinical 
trials in HL. Accordingly, also for thiazolidinediones (a class of peroxisome 
proliferator-activated receptor γ agonists) that have growth-inhibitory effects on 
transformed cells, no studies have been conducted in HL. At a time of personalized 
cancer therapy, there is an unmet need for targeted therapeutic approaches for patients 
with obesity and cancer, namely HL. Thereby, future research should focus on the 
manipulation of adipocyte biology (e.g. enhance adiponectin synthesis, stimulate intra-
adipocyte lipid oxidation and promote reactivation/conversion of brown adipose tissue) 
[136], in order to promote health and benefit patients. With a pace of discovery 
indicating that adipose tissue-cancer field is rapidly growing, with new insights 
unfolding for many cancer types, it remains to be seen how well we will translate these 







Notwithstanding our present inability to explain potential mechanisms 
underlying the association between adiposity and improved prognosis following 
chemotherapy in HL, we believe that the role of adiposity should be explored in 
prospective cohorts. Although recent studies support a positive but weak causally 
related epidemiological association between obesity and HL, here we propose that 
stronger evidence would emanate from using more precise methods for evaluating both 
whole body and local fatness.  
Though the molecular rationale has not yet been convincingly elucidated in the 
literature, inflammation is common to obesity and Hodgkin's lymphoma. In fact, the 
tumor microenvironment, particularly the repertoire of non-neoplastic cells and 
molecules produced by them, seem to exert a strong influence on tumor cell growth, 
evasion, survival and diversion of immunological mechanisms. The obesity-HL 
association could reflect the interaction of molecules produced by adipocytes in the 
tumor microenvironment and the HRS cells. Some molecules, such as IL-6, IL3, IL-7, 
TNF-α, YKL-40, and NF-kB and JAK/STAT pathways seem to support this 
association. In a topic where the literature has not provided the luxury of clinical trials 
and data, the development of new molecular biomarkers, based on adipokine pathways, 
may add information as clinical outcome predictors. Their incorporation into prognostic 
models may improve our understanding of the biologic correlates of obesity and HL. 
Moreover, if demonstrated, mediators of the effect of adipocytes in bone marrow 
metastatic Hodgkin’s lymphoma microenvironment represent an additional potential 
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Figure 1. Endocrine effects of obesity impact Hodgkin Reed-Sternberg lymphoma cells. 
Excess adiposity modulates HRS aggressiveness in lymph nodes through a systemic 
effect mediated by adipokines and migrating adipose stem cells. In obesity states the 
adipose tissue acquires the following characteristics: hypertrophied adipocytes, 
neoangiogenesis with increased vessel density, infiltration with M1 type macrophages, 
increased amount of adipose stem cells and upregulated secretion of pro-tumoral 
adipokines whereas anti-tumoral adipokines are downexpressed (e.g. adiponectin, 
SHBG and LOX). The full black arrow represents adipokines and adipose stem cells 
entering peripheral blood. The circulation levels of these adipokines are significantly 
increased in obese (as opposed to adiponectin levels), reaching lymph nodes, where 
they may induce either direct effects to HRS cells through direct binding to cell 
receptors or indirect actions by interaction with cells in microenvironment modulating 
their crosstalk with HRS cells. Ultimately, adipokines may induce intracellular 
signalling pathways (represented by solid black arrows within HRS cell) and 
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mechanisms that will lead to angiogenesis, and to cell proliferation, cell migration, 
DNA damage or anti-apoptosis of HRS cells. AKT, Akt kinase; C/EBPβ, 
CCAAT/enhancer binding protein beta; CRP, C-reactive protein; ER, endoplasmic 
reticulum; ECM, extracellular matrix; FGF, fibroblast growth factor; FFA, free-fatty 
acids; HGF, hepatocyte growth factor; HRS, Hodgkin Reed-Sternberg cell; IGF-1, 
insulin-like growth factor-1; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-8, 
interleukin 8; JAK, Janus kinase; LOX, lysyl oxidase; mTOR, mammalian target of 
rapamycin; MMP, matrix metalloproteinase; MAPK, mitogen-activated protein kinase; 
MCP-1, monocyte chemoattractant protein 1; NGF, nerve growth factor; NF-kB, 
nuclear factor kappa B; PAI-1, plasminogen activator inhibitor–1; PI3K, 
phosphatidylinositol 3'–kinase; PlGF, placental growth factor; PPARγ, peroxisome 
proliferator-activated receptor gamma; RANTES (CCL5), regulated on activation, 
normal T cell expressed and secreted; ROS, reactive oxygen species; SHBG, sex 
hormone binding globulin; STAT, signal transducer and activator of transcription; SDF-
1, stromal derived factor 1; TGFβ, transforming growth factor beta; TNF-α, tumor 
necrosis factor alpha; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular 
endothelial growth factor 
 
Figure 2. Hypothetical role of obesity and adipocytes in the bone marrow 
microenvironment invaded by HRS cells. This figure depicts the complex interaction 
between cellular components in the bone marrow and its mediators, particularly the 
contribution of bone marrow adipocytes to bone homeostasis and metastatic 
progression. Most adipokines produced in adipocytes (leptin, VEGF, osteopontin, TNF-
α, MMP9, IL-1, IL-6, TGF-β, IGF-1, MCP-1) may contribute either directly (through 
an effect in HRS tumor cells mediated by their specific receptor downstream signalling 
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– impacting HRS cell motility, survival and proliferation) or indirectly (by influencing 
other cells in the microenvironment, including osteoblasts, osteoclasts, lymphocytes, 
macrophages, endothelial and mesenchymal stem cells, to acquire an pro-tumoral 
behaviour – immunological modulation, increased chemotaxis, cell differentiation, 
matrix reorganization, neoangiogenesis, increased osteoclast recruitment and activation, 
ultimately resulting in bone resorption and osteolytic metastatic lesions) to this stage 
aggressiveness and HL prognosis. Solid black lines with arrows represent secretion or 
the effect of a given adipokine, whereas dashed lines denote inhibitory action. Multiple 
light yellow arrows mean the reciprocal impact other cells might have in adipocytes. 
AdipoQ, adiponectin; CTSK, cathepsin K; DKK-1, dickkopf-related protein 1; FAs, 
fatty acids; IL-1, interleukin 1; IL-3, interleukin 3; IL-7, interleukin 7; IL-10, 
interleukin 10; MMP9, matrix metalloproteinase 9; MSCs, mesenchymal stem cells; 
OPG, osteoprotegerin; PGE2, prostaglandin E2; RANKL, receptor activator of nuclear 
factor kappa-B ligand; SPARC, osteonectin. 
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